Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

Similar articles for PubMed (Select 24900633)

1.

Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors.

Huang H, Guzman-Perez A, Acquaviva L, Berry V, Bregman H, Dovey J, Gunaydin H, Huang X, Huang L, Saffran D, Serafino R, Schneider S, Wilson C, DiMauro EF.

ACS Med Chem Lett. 2013 Oct 21;4(12):1218-23. doi: 10.1021/ml4003315. eCollection 2013 Dec 12.

2.

Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.

Johannes JW, Almeida L, Barlaam B, Boriack-Sjodin PA, Casella R, Croft RA, Dishington AP, Gingipalli L, Gu C, Hawkins JL, Holmes JL, Howard T, Huang J, Ioannidis S, Kazmirski S, Lamb ML, McGuire TM, Moore JE, Ogg D, Patel A, Pike KG, Pontz T, Robb GR, Su N, Wang H, Wu X, Zhang HJ, Zhang Y, Zheng X, Wang T.

ACS Med Chem Lett. 2015 Jan 13;6(3):254-9. doi: 10.1021/ml5003663. eCollection 2015 Mar 12.

PMID:
25815142
3.

Crystal structure of a Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate recruitment.

Morrone S, Cheng Z, Moon RT, Cong F, Xu W.

Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1500-5. doi: 10.1073/pnas.1116618109. Epub 2012 Jan 17.

4.

Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.

Bregman H, Chakka N, Guzman-Perez A, Gunaydin H, Gu Y, Huang X, Berry V, Liu J, Teffera Y, Huang L, Egge B, Mullady EL, Schneider S, Andrews PS, Mishra A, Newcomb J, Serafino R, Strathdee CA, Turci SM, Wilson C, DiMauro EF.

J Med Chem. 2013 Jun 13;56(11):4320-42. doi: 10.1021/jm4000038. Epub 2013 May 23.

PMID:
23701517
5.

[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.

Shultz MD, Kirby CA, Stams T, Chin DN, Blank J, Charlat O, Cheng H, Cheung A, Cong F, Feng Y, Fortin PD, Hood T, Tyagi V, Xu M, Zhang B, Shao W.

J Med Chem. 2012 Feb 9;55(3):1127-36. doi: 10.1021/jm2011222. Epub 2012 Feb 1.

PMID:
22260203
6.

Evidence for tankyrases as antineoplastic targets in lung cancer.

Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ.

BMC Cancer. 2013 Apr 28;13:211. doi: 10.1186/1471-2407-13-211.

7.

Structure-Based Design of Potent and Selective CK1γ Inhibitors.

Huang H, Acquaviva L, Berry V, Bregman H, Chakka N, O'Connor A, DiMauro EF, Dovey J, Epstein O, Grubinska B, Goldstein J, Gunaydin H, Hua Z, Huang X, Huang L, Human J, Long A, Newcomb J, Patel VF, Saffran D, Serafino R, Schneider S, Strathdee C, Tang J, Turci S, White R, Yu V, Zhao H, Wilson C, Martin MW.

ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64. doi: 10.1021/ml300278f. eCollection 2012 Dec 13.

8.

A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.

Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, Magnuson S, Sambrone A, Schutten M, Firestein R, Machon O, Korinek V, Choo E, Diaz D, Merchant M, Polakis P, Holsworth DD, Krauss S, Costa M.

Cancer Res. 2013 May 15;73(10):3132-44. doi: 10.1158/0008-5472.CAN-12-4562. Epub 2013 Mar 28.

9.

Structure, Dynamics and Functionality of Tankyrase Inhibitor-induced Degradasomes.

Thorvaldsen TE, Pedersen NM, Wenzel EM, Schultz SW, Brech A, Liestol K, Waaler J, Krauss S, Stenmark H.

Mol Cancer Res. 2015 Jun 29. pii: molcanres.0125.2015. [Epub ahead of print]

PMID:
26124443
10.

Scaffold hopping approach on the route to selective tankyrase inhibitors.

Liscio P, Carotti A, Asciutti S, Ferri M, Pires MM, Valloscuro S, Ziff J, Clark NR, Macchiarulo A, Aaronson SA, Pellicciari R, Camaioni E.

Eur J Med Chem. 2014 Nov 24;87:611-23. doi: 10.1016/j.ejmech.2014.10.007. Epub 2014 Oct 5.

PMID:
25299683
11.

Design and Discovery of 2-Arylquinazolin-4-ones as Potent and Selective Inhibitors of Tankyrases.

Nathubhai A, Wood PJ, Lloyd MD, Thompson AS, Threadgill MD.

ACS Med Chem Lett. 2013 Oct 15;4(12):1173-7. doi: 10.1021/ml400260b. eCollection 2013 Dec 12.

12.

Exploration of the nicotinamide-binding site of the tankyrases, identifying 3-arylisoquinolin-1-ones as potent and selective inhibitors in vitro.

Paine HA, Nathubhai A, Woon EC, Sunderland PT, Wood PJ, Mahon MF, Lloyd MD, Thompson AS, Haikarainen T, Narwal M, Lehtiö L, Threadgill MD.

Bioorg Med Chem. 2015 Jul 2. pii: S0968-0896(15)00555-6. doi: 10.1016/j.bmc.2015.06.061. [Epub ahead of print]

PMID:
26189030
13.

Structural basis and selectivity of tankyrase inhibition by a Wnt signaling inhibitor WIKI4.

Haikarainen T, Venkannagari H, Narwal M, Obaji E, Lee HW, Nkizinkiko Y, Lehtiö L.

PLoS One. 2013 Jun 6;8(6):e65404. doi: 10.1371/journal.pone.0065404. Print 2013.

14.

A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.

Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova O, Gradl D, Voronkov A, von Kries JP, Krauss S.

Cancer Res. 2012 Jun 1;72(11):2822-32. doi: 10.1158/0008-5472.CAN-11-3336. Epub 2012 Mar 22.

15.

para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.

Haikarainen T, Koivunen J, Narwal M, Venkannagari H, Obaji E, Joensuu P, Pihlajaniemi T, Lehtiö L.

ChemMedChem. 2013 Dec;8(12):1978-85. doi: 10.1002/cmdc.201300337. Epub 2013 Oct 15.

PMID:
24130191
16.

Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells.

Bao R, Christova T, Song S, Angers S, Yan X, Attisano L.

PLoS One. 2012;7(11):e48670. doi: 10.1371/journal.pone.0048670. Epub 2012 Nov 7.

17.

Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.

Nkizinkiko Y, Suneel Kumar BV, Jeankumar VU, Haikarainen T, Koivunen J, Madhuri C, Yogeeswari P, Venkannagari H, Obaji E, Pihlajaniemi T, Sriram D, Lehtiö L.

Bioorg Med Chem. 2015 Aug 1;23(15):4139-49. doi: 10.1016/j.bmc.2015.06.063. Epub 2015 Jul 2.

PMID:
26183543
18.

Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.

Kulak O, Chen H, Holohan B, Wu X, He H, Borek D, Otwinowski Z, Yamaguchi K, Garofalo LA, Ma Z, Wright W, Chen C, Shay JW, Zhang X, Lum L.

Mol Cell Biol. 2015 Jul;35(14):2425-35. doi: 10.1128/MCB.00392-15. Epub 2015 May 4.

PMID:
25939383
19.

Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.

Hua Z, Bregman H, Buchanan JL, Chakka N, Guzman-Perez A, Gunaydin H, Huang X, Gu Y, Berry V, Liu J, Teffera Y, Huang L, Egge B, Emkey R, Mullady EL, Schneider S, Andrews PS, Acquaviva L, Dovey J, Mishra A, Newcomb J, Saffran D, Serafino R, Strathdee CA, Turci SM, Stanton M, Wilson C, Dimauro EF.

J Med Chem. 2013 Dec 27;56(24):10003-15. doi: 10.1021/jm401317z. Epub 2013 Dec 11.

PMID:
24294969
20.

Structural basis of selective inhibition of human tankyrases.

Narwal M, Venkannagari H, Lehtiö L.

J Med Chem. 2012 Feb 9;55(3):1360-7. doi: 10.1021/jm201510p. Epub 2012 Jan 25.

PMID:
22233320
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk